inhibitory glp 1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1R agonists: Full of hope,

Coverage at NY Times, front page today and my input to that piece To view or add a comment, sign in Pseudoscience So heres the whole story on why the FDA is endorsing peptides where there is a lack of solid scientific evidence that they have any effect eg on inflammation, weight loss, longeivity Essentially they added 6 people to the decision making committee who had a specific interests in supporting the sale of these peptides

For LipoEmulsion to become a validated BPC delivery technology rather than a proprietary formulation claim, I would want to see: particle or droplet-size distribution encapsulation efficiency intact-peptide stability over the stated shelf life ex vivo buccal-permeability testing comparison with an ordinary BPC solution human plasma concentration-time data absolute or relative bioavailability InfiniWell says it has aggregated population-health data from more than 3,000 members

What are the potential side effects, and how can they be managed

These results indicated that BoNT/X evolution was continuing toward improved recognition of authentic gasdermin D substrates

Check manufacturer assistance programs

That's the power of peptides